Cyclopamine

For research use only. Not for use in humans.

目录号：S1146 别名： 11-deoxojervine 中文名称：环巴胺

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

规格

价格

库存

购买数量

5mg	RMB 1227.56	现货
25mg	RMB 3037.37	现货
50mg	RMB 3833.48	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cyclopamine发表文献74篇：

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)418

PubMed: 33499351 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

Cell Rep, 2020, 21;31(3):107521

PubMed: 32320667 ( click the link to review the publication )

Int J Cancer, 2020, 7

PubMed: 32383186 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30192-2

PubMed: 32589876 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):488

PubMed: 33198821 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 20;2020:1868764

PubMed: 32377291 ( click the link to review the publication )

Proc Biol Sci, 2020, 287(1935):20192939

PubMed: 32933441 ( click the link to review the publication )

Chemosphere, 2020, 6;254:126709

PubMed: 32348926 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6410

PubMed: 32899202 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.2873

PubMed: 32030915 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2610-2620

PubMed: 33125122 ( click the link to review the publication )

Front Pharmacol, 2020, 11:204

PubMed: 32194421 ( click the link to review the publication )

Neural Plast, 2020, 2020:8815195

PubMed: 32802036 ( click the link to review the publication )

Dev Cell, 2019, 51(6):665-674.e6

PubMed: 31813796 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3134-3152

PubMed: 31371388 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )
Hum Mol Genet, 2019, 28(6):896-911

PubMed: 30445456 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(8)E1991

PubMed: 31018557 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5386-5395

PubMed: 30367510 ( click the link to review the publication )

J Cell Biochem, 2019, 120(11):18979-18994

PubMed: 31245876 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2019, 124(6):660-669

PubMed: 30548093 ( click the link to review the publication )

Hepatobiliary Pancreat Dis Int, 2019, 18(1):38-47

PubMed: 30243878 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Lab Chip, 2018, 18(20):3184-3195

PubMed: 30204194 ( click the link to review the publication )

Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Mol Pain, 2018, 14:1744806918767560

PubMed: 29607715 ( click the link to review the publication )

Biol Reprod, 2018, 98(4):480-490

PubMed: 29329377 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Cell Transplant, 2018, 27(3):393-406

PubMed: 29749250 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

PLoS Genet, 2017, 13(8):e1006951

PubMed: 28797033 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):568-578

PubMed: 27709831 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )
Mol Immunol, 2017, 92:68-75

PubMed: 29054053 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42495-42509

PubMed: 28477008 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):682-94

PubMed: 27113760 ( click the link to review the publication )

J Med Chem, 2016, 59(24):11050-11068

PubMed: 27736063 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Int J Mol Med, 2015, 35(6):1641-50

PubMed: 25872645 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):544-59

PubMed: 24553082 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 5;32(1):7

PubMed: 23379358 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )
Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

靶点

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

体外研究

Cyclopamine 抑制Hedgehog信号通路， IC50 为46 nM, 且在[3H]Hh-Ag结合实验中，作用于CHO-K1细胞，抑制人类Smo受体活性，IC50为 280 nM。^[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞，显著抑制 Hedgehog通路活性，这种作用存在剂量依赖性，且浓度为3 μM时，抑制肿瘤细胞生长，抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果，说明Cyclopamine 特定作用于Hedgehog 通路，且没有毒性。^[2]通过与Smo直接作用而抑制Hedgehog信号，Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖，抑制达 75-80%,且使凋亡率提高2.5到 3.5倍，但是不影响BxPC3-SMOlow 细胞系。^[3] Cyclopamine 处理E3LZ10.7细胞系，显著降低Snail mRNA，且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞，显著抑制浸润型细胞, 使转移细胞降低500多倍，但是对Hedgehog非依赖性细胞系Panc-1没有影响。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
OS-RC-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M36wcWlEPTB;NT64OlY3KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
DOHH-2	NVrE[nlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVLwb4pLUUN3ME25MlM2Pjh7IN88US=>	M33VelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
no-10	NHfrUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVnJR\|UxRTlwOUCzPUDPxE1?	NHWxe3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LS-513	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHLiN2VKSzVyPUGxMlM2PDdizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ALL-PO	M1fGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWTmR\|V1UUN3ME2xNU44PzN2IN88US=>	M2eySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
8-MG-BA	NYnTZolTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEjYeIlKSzVyPUGzMlEyOjNizszN	NYWyXIlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RPMI-8402	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoTzTWM2OD1zNT64OVM4KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
EoL-1-cell	NGTWTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTF6LkW5OFgh\|ryP	NHy0W2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NALM-6	NUDOVWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MonaTWM2OD1zOT6wNVY4KM7:TR?=	M4r0blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
DEL	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1ewdWlEPTB;MkCuNVQ4OSEQvF2=	Mnr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SR	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTJ\|Lk[3NVUh\|ryP	NW\ES\|Y2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
697	M2TUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF\Qc5VKSzVyPUK2MlYyPTVizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
COLO-829	NHGxVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoXNTWM2OD1{Nj64OFg{KM7:TR?=	MmrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
EVSA-T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGfFU2JKSzVyPUK3MlU2PjFizszN	M{[zN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ATN-1	NX73flhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVTJR\|UxRTNzLkKzNlkh\|ryP	NF\VNmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
L-363	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYq5NHRqUUN3ME2zNU44PDZzIN88US=>	MlyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LAMA-84	NXH2T3oyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmCyTWM2OD1\|Mj61NlEyKM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYjNWIliUUN3ME2zOE4zQTV4IN88US=>	MmHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BB30-HNC	M37JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{WyNWlEPTB;M{SuN\|MxPiEQvF2=	NHvnR3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BC-1	NVfUZXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV;GfYpOUUN3ME2zO{46PzR4IN88US=>	NH\FPWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
IST-SL2	M3TOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3TrbWlEPTB;M{iuNlI1KM7:TR?=	M4PLXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
D-392MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWnCUZpKUUN3ME20NE4zOjF3IN88US=>	MlnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
no-11	NVfpSoc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4flNWlEPTB;NECuOVUzOSEQvF2=	NUG4XY1yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LC4-1	NXzJWI1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWnJR\|UxRTRyLki3NVYh\|ryP	NV:1OVUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
A388	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3vzcGlEPTB;NEKuOVg1QCEQvF2=	M33BbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\4XJBuUUN3ME20Nk44ODd2IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
CESS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1LNcWlEPTB;NESuNlI{OiEQvF2=	NVjxWJNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RS4-11	NYjGWZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYXJR\|UxRTR7LkC5N\|gh\|ryP	M{K2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MS-1	NHjvcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVzJR\|UxRTVyLkmzOVEh\|ryP	NHPiW4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CTV-1	NULDbnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVXJR\|UxRTVzLkC3OEDPxE1?	NIjZW2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-502MG	NX\Ke5FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUWxWJZnUUN3ME21NU43OjdzIN88US=>	NG\FTIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ML-2	NIPlemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXrRTXp7UUN3ME21Nk46OTl3IN88US=>	M3rGblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SK-NEP-1	NYrUN3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUjyNW92UUN3ME21N{4{QTJ\|IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LOXIMVI	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4DweWlEPTB;NUOuOVg5PCEQvF2=	MmjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
DJM-1	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIrHSnBKSzVyPUW2MlM{QTFizszN	NV62e2ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
GI-1	NUDC[4FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkLnTWM2OD13Nj62NVQ6KM7:TR?=	Ml\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
IST-MES1	NWKweFc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYTk[5o4UUN3ME22NE42PDl\|IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MV-4-11	NGqwfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEXieXBKSzVyPU[wMlY2OzhizszN	M2TDXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
OVCAR-4	NXWzdHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{L4XWlEPTB;NkOuOVY2PyEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KE-37	NIL1TIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGj3XndKSzVyPU[2MlI3PjhizszN	NV3XTnlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-542MG	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEHod3RKSzVyPU[4MlQyOzVizszN	M2W3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	NEPIRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTd{Lki0OFEh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MRK-nu-1	NXHqSFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3:zeWlEPTB;N{OuOFcxPSEQvF2=	NFrYUXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-247MG	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NITaN5ZKSzVyPUezMlU1PDJizszN	NEXzRpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
OCI-AML2	MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUPwPJNSUUN3ME23Ok46OzZ7IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LP-1	M3HZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoHETWM2OD16Mj64O\|MyKM7:TR?=	M4nr[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HCC1599	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3vMcWlEPTB;OESuNlg{PyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-45	NHW5XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXvJR\|UxRTh2Lk[5PVIh\|ryP	NEXReG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BE-13	NIjlfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFHQb4FKSzVyPUm5MlA1PzdizszN	NGfLUGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GCIY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4Xj[GlEPTB;OUmuNFk2PCEQvF2=	MkThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BV-173	NXzRXHhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEKzcXRKSzVyPUGwNE4{OjVizszN	NVXTdW5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB2518-MEL	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX\JR\|UxRTFyMD63PFkh\|ryP	M3rQU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KS-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkfNTWM2OD1zMEGuOlM6KM7:TR?=	NWfNWZFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
MOLT-16	NFL4[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{[1O2lEPTB;MUC0Mlk5PiEQvF2=	M1yybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-H1770	M{XkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MknhTWM2OD1zMEiuO\|g1KM7:TR?=	NEH1WZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H82	M4LSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUTJR\|UxRTFzMD65O\|Yh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCCIT	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFrkdlFKSzVyPUGxNk42OjlizszN	MknhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KALS-1	NEj5OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVXDd3ZnUUN3ME2xNVUvQTRzIN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB2241-RCC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mmn2TWM2OD1zMU[uOlc6KM7:TR?=	NFr1co09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HH	NYPiPYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWXJR\|UxRTFzNz6zPVUh\|ryP	M3LkT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HD-MY-Z	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NY\N[mlCUUN3ME2xNVgvPDh6IN88US=>	M2S1V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
EB-3	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYfJR\|UxRTF{Mz6wPVQh\|ryP	MoTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BL-70	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXX2UWxHUUN3ME2xNlMvOTJ5IN88US=>	M3LLVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
K-562	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2rlUWlEPTB;MUK2MlI1PSEQvF2=	NGLxV3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HT-144	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYXo[\|NDUUN3ME2xN\|MvOTZ2IN88US=>	NVfXTpJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
PF-382	NEniTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnnETWM2OD1zM{SuN\|YyKM7:TR?=	MlrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
RPMI-8226	M3LiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkDpTWM2OD1zM{WuNFQ2KM7:TR?=	NXHQNJNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1355	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF7GN4dKSzVyPUGzOU42QDdizszN	NW\zXW1bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LXF-289	NUDGdVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M33pbWlEPTB;MUO5Mlc5OSEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H69	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHTZZ3hKSzVyPUG0Nk46OzJizszN	MlTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	NX31[\|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUPzV5BDUUN3ME2xOFcvOTNizszN	MljSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KARPAS-299	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTF2OT6xNkDPxE1?	Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
GB-1	NF7qbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFroU2VKSzVyPUG0PU4{OjJizszN	M3XoZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
CMK	NYP5UoxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2P0PWlEPTB;MUS5MlUyPSEQvF2=	NHXsZlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MPP-89	NV7VbIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH\MPGFKSzVyPUG1Ok4xOzVizszN	NF7uXmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KU812	NHXsSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIT3dFRKSzVyPUG2NU46ODJizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
REH	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1\rbGlEPTB;MU[yMlEzPSEQvF2=	M13afFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NEC8	NGDUVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXfJR\|UxRTF4NT6wNlYh\|ryP	M2jOSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KP-N-YS	NUHKfnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHFTWM2OD1zNkiuN\|k2KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	NFvnU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnrsTWM2OD1zNkmuPVE2KM7:TR?=	NYLtXVV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Becker	NYj0c4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mmj0TWM2OD1zN{SuNVgh\|ryP	NVzEfWU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB647-SCLC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITHOVhKSzVyPUG3OU45PDVizszN	M3\0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LU-139	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYL3SWJzUUN3ME2xO\|gvODF7IN88US=>	NGrjXnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
QIMR-WIL	M1fJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWD4cXlOUUN3ME2xO\|kvPjR4IN88US=>	NVvPSIk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1395	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHTTWM2OD1zN{muPVk3KM7:TR?=	M{LCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NOMO-1	M2rrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1nyN2lEPTB;MUiyMlg2KM7:TR?=	NW\pS3ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
GI-ME-N	NYHWW5BGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV64SXExUUN3ME2xPFcvQTZ7IN88US=>	M2q3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KMS-12-PE	M{HvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXjJR\|UxRTF6OT6yO\|Mh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
Daudi	MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXPJR\|UxRTF7MT6xNlgh\|ryP	NIj6VJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LB996-RCC	NV[0VZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYXJR\|UxRTF7MT62PVkh\|ryP	NH3QU4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H2107	M2XDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTF7Mz63N\|kh\|ryP	M3P1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SK-PN-DW	NHzLT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3SyPGlEPTB;MUm0MlcyQSEQvF2=	NFX4b2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MC-CAR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M16xWmlEPTB;MkCyMlI2OyEQvF2=	NXe1SGdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SNB75	M1PiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnzUTWM2OD1{MkGuPVQh\|ryP	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ES4	NGXMV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MonqTWM2OD1{MkOuO\|g{KM7:TR?=	NXLVXllKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KARPAS-422	MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MY\JR\|UxRTJ{OD6zOVIh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1648	Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHTJb5BKSzVyPUKyPU41QDlizszN	NFv5RYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ES6	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXvJR\|UxRTJ\|OT60N{DPxE1?	MmfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KNS-81-FD	NH;xflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnfFTWM2OD1{NEGuNVk4KM7:TR?=	NYLmRmdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
JAR	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYTEVJVRUUN3ME2yOVYvOjJ3IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NB1	NGTCeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MY\JR\|UxRTJ4MD61NVYh\|ryP	M{L4O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
D-336MG	NELSSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYTGd5VQUUN3ME2yOlAvPjl6IN88US=>	NGL6OlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
BC-3	M2rtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkS2TWM2OD1{NkWuNVc5KM7:TR?=	MmrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC2218	NW\T[IZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXKWFJqUUN3ME2yOlYvPDF3IN88US=>	M3vae\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
TE-9	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml\vTWM2OD1{Nk[uOlI4KM7:TR?=	NYHqcWJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmLhTWM2OD1{Nk[uO\|U{KM7:TR?=	MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
CTB-1	M4D0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1jsWmlEPTB;Mk[5Mlk4OyEQvF2=	M1X3clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NB7	M{j4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml\lTWM2OD1{N{Gg{txO	NWnSRpV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ST486	NYf3VItwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFHXbnJKSzVyPUK3O{41OTJizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HCC1187	NIjUblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3;0d2lEPTB;MkiyMlgyOSEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-SNU-16	M2jJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFywc5FKSzVyPUK4OE4zPDhizszN	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
COR-L279	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVTiVWdpUUN3ME2yPVEvPTh2IN88US=>	MmW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ES8	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NE\HTlZKSzVyPUK5OE4yQDJizszN	MkK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U-698-M	NUXrXZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnLtTWM2OD1{OUiuNlQ{KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HEL	NFmyN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWPJR\|UxRTNyOT6xOFkh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KINGS-1	M3;RTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlTNTWM2OD1\|MUCuOlc1KM7:TR?=	MoTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KY821	M4TtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2DybWlEPTB;M{O2MlU6PSEQvF2=	MnXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MZ1-PC	NEjj[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHjER4dKSzVyPUO0OU43OThizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LS-411N	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFLhNZZKSzVyPUO1OE43PiEQvF2=	M4P0NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
SIG-M5	NVLYTphFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHHhWZpKSzVyPUO1PU44QDJizszN	M1rC[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HT	NIPJT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGT2RplKSzVyPUO2O{44OTFizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2m3emlEPTB;M{[3Mlc5PyEQvF2=	NXS4TllkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NCI-H1694	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVjJR\|UxRTN5Mj65N\|Qh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BB65-RCC	NHHyWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX;JR\|UxRTN5Nj6yOFUh\|ryP	NGj4boM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HAL-01	NX7GXWdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlXZTWM2OD1\|N{muPFM5KM7:TR?=	NVnDO3V5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ARH-77	M2\keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWXLSZZxUUN3ME2zPVQvODB6IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MZ7-mel	NV\NRZcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml3XTWM2OD1\|OUeuNlM{KM7:TR?=	MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SIMA	NUDyfmVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHyTWM2OD12MEOuPVM{KM7:TR?=	NGi4fpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
DG-75	M4fMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHfOSmpKSzVyPUSxOU43QThizszN	NUS4U3ZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
HUTU-80	M{fZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4\6T2lEPTB;NEG5MlE5PSEQvF2=	NUjVTVVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KNS-42	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4Pq[2lEPTB;NEK1MlgyPSEQvF2=	NYGxWXU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SH-4	NIH0S3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlyyTWM2OD12MkeuOVY2KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
L-540	NYTKUHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVfUUHg2UUN3ME20N\|EvODNzIN88US=>	NFy4cXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NB10	NFzRWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnTsTWM2OD12NEGuNlM1KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES1	NYrvXJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoHJTWM2OD12NUKuO\|U{KM7:TR?=	NWnrZ\|JJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KMOE-2	NVf4PZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVHJR\|UxRTR3Nj63NVEh\|ryP	M3r0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MC116	NYWzfYxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NETEbmpKSzVyPUS1PE4yOTZizszN	NUTPXZFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RCC10RGB	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4j1SWlEPTB;NE[wMlAxPSEQvF2=	NETjcow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RL95-2	MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUHJR\|UxRTR4MD6yN\|ch\|ryP	NUm3SoxERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Raji	NGPoW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVLJR\|UxRTR4OD6xOFMh\|ryP	NEnKb4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
CAS-1	NE\IfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGPkfHlKSzVyPUS3Nk4xPzNizszN	NIXkepQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
Calu-6	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MknFTWM2OD12N{WuNlY2KM7:TR?=	M2j2T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KG-1	NULITVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlrwTWM2OD12N{iuOFQh\|ryP	NInsZ5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
LB771-HNC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXvueXVNUUN3ME20PFIvOjN{IN88US=>	NVfqWlBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ACN	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVPJR\|UxRTR7Mz61PVkh\|ryP	M3G1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KM12	M4LKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkG2TWM2OD12OU[uOVg6KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
U2OS	NH;OfFBHfW6ldHnvckBie3OjeR?=			M3n3NmJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKFOvbzDlfJBz\XO\|ZXSgbY4hXTKRUzDj[YxteyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNZDC9JFAvODF{NDFOwG0v	NFzudFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
U2OS	M3nEe2Z2dmO2aX;uJIF{e2G7		NG\4UYQzKGi{cx?=	M2\kOWRqe3CuYXPlcYVvfCCxZjDbN2he[3mlbH;wZY1qdmViZoLvcUB4cWymIIT5dIUhW22xIHX4dJJme3OnZDDpckBWOk:VIHPlcIx{KGGodHXyJFIhcHK\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvpJF0hOC5yMUK3JO69VS5?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
TM3	MkfBSpVv[3Srb36gZZN{[Xl?		MlTGOFghcHK\|	NFT2fFRKdmirYnn0bY9vKG:oIFjl[IdmcG:pIIPp[45idGmwZzDwZZRpf2G7IHnuJI1wfXOnIGTNN{Bk\WyuczDi[YFzcW6pIIDURU05gEeuaT3MeYMhemWyb4L0[ZIh[2:wc4TyeYN1KGG\|c3Xzd4VlKGG\|IITyZY5{[3KrcITpc45idCCvb3T1cIF1cW:wIH;mJGdtcSCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SCjc4PhfUwhUUN3MDC9JFAvODR4IN88UU4>	M1TCWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEmxOVU6Lz5zOUC5NVU2QTxxYU6=
HCC827	MVLGeY5kfGmxbjDhd5NigQ>?			NIG1eFFFcXOybHHj[Y1mdnRib3[gX\|NJZS2leXPsc5BidWmwZTDmdo9uKFOPTzDWOFA1VSCvdYThcpQhcW5iZ3XmbZRqdmmkIILld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygT4khRSByLkC1NUDPxE1w	M1fYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{i3NVU3Lz5{OEe4O\|E2PjxxYU6=
HEK293	M{W5UmZ2dmO2aX;uJIF{e2G7		M2r4V\|IhcHK\|	MX7EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWyjYnXscIVlKGO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHluIFnDOVAhRSByLkC2OEDPxE1w	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
Shh Light2	NF;4d4RHfW6ldHnvckBie3OjeR?=		NXrVeZN5OzBiaILz	M{fjTmlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViU3joJGxq\2i2MjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHOxbnnjJIhm\GenaH;nMYlv\HWlZXSgS2xKOS2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhdWWjc4Xy[YQh[W[2ZYKgN\|AhcHK\|IHL5JIR2[WxibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4xPzRzIN88UU4>	NIqy[nM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W2O\|M4OSd-Mke1Olc{PzF:L3G+
U2OS	M16yN2Z2dmO2aX;uJIF{e2G7			NY\4doRmSmmwZHnu[{Bi\m[rbnn0fUB1dyCVbX:gSFQ4O0hibYX0ZY51KGW6cILld5Nm\CCrbjDVNm9UKGOnbHzzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGtlKD1iMD6xNVYh\|ryPLh?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
DaOY	NXHJO3VZTnWwY4Tpc44h[XO\|YYm=		M4LPOlQ5KGi{cx?=	MkK4TY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gbJVu[W5iRHHPXUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBIdGlzIH3SUmEh\XiycnXzd4lwdiCjZoTldkA1QCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzMEBKSzVyIE2gNE4yPiEQvF2u	Ml20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
U2OS	M171NGZ2dmO2aX;uJIF{e2G7		NUf1O2VROiCqcoO=	MWrEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32gV41wKER2N{PIJI12fGGwdDDlfJBz\XO\|ZXSgbY4hXTKRUzDj[YxteyCjZoTldkAzKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDBwMkOyJO69VS5?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
CHO	MkPPSpVv[3Srb36gZZN{[Xl?			MXrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHNudyC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KFt\|SG3IbE1C\yCkaX7kbY5oKGG\|c3H5MEBKSzVyIE2gNE4zQCEQvF2u	NE\Ue3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5NVU2QSd-MUmwPVE2PTl:L3G+
Shh Light2	Mmm1SpVv[3Srb36gZZN{[Xl?		NIexfGo1OCCqcoO=	MX\Jcohq[mm2aX;uJI9nKFOKSDDwZZRpf2G7IHnuJI1wfXOnIGPobEBNcWeqdEKgZ4VtdHNiYX\0[ZIhPDBiaILzJIJ6KEeuaT3k[ZBmdmSnboSgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwJF0hOC5\|IN88UU4>	MnjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3OUK3PFgoRjJzNUmyO\|g5RC:jPh?=
Shh-light2	NGXNOJVHfW6ldHnvckBie3OjeR?=			MoTPTY5pcWKrdHnvckBw\iCVbX:tcYVlcWG2ZXSgTIghe2mpbnHsbY5oKGmwIHj1cYFvKFOqaD3sbYdpfDJiY3XscJMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBKSzVyIE2gNE4{KM7:TT6=	M17PdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
M210B4	MXzGeY5kfGmxbjDhd5NigQ>?		Mn;tNlQhcHK\|	NXnRTHRkUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegbY4hdW:3c3WgUVIyOEJ2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTve45z\We3bHH0bY9vKG:oIGD0Z4ghdVKQQTDlfJBz\XO\|aX;uJIFnfGW{IEK0JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNuIFnDOVAhRSByLkSzJO69VS5?	NVTnV5B5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
Shh-Light 2	M3jiXWZ2dmO2aX;uJIF{e2G7		NIjyPHkzKGSjeYO=	MYPBcpRi\2:waYP0JIFkfGm4aYT5JIF1KFOvbzDpckBud3W\|ZTDTbIguVGmpaISgNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPobE1qdmS3Y3XkJGdtcTFvcnXwc5J1\XJiYXP0bZZqfHliYX\0[ZIhOiCmYYnzJIJ6KGS3YXytcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIH3leIhw\CxiSVO1NEA:KDBwNEi0JO69VS5?	NVzFeoljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
Shh Light2	M{DkbmZ2dmO2aX;uJIF{e2G7			Mn\4TY5pcWKrdHnvckBw\iCVSFigbY4hdW:3c3WgV4hpKEyrZ3j0NkBk\WyuczDifUBIVElvcnXzdI9ve2m4ZTDmbZJm\my7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvPSEQvF2u	NXKzNW03RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFkxQDBpPkG5N\|A6ODhyPD;hQi=>
C3H10T1/2	NYHQVGJSTnWwY4Tpc44h[XO\|YYm=			NFvYOnVKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygV2hJKGGldHn2ZZRm\CCyYYToe4F6KGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCVQVetbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvckBjgSCjbHvhcIlv\SCyaH;zdIhifGG\|ZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v	NUXK[41VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1PVI4QDhpPkKxOVkzPzh6PD;hQi=>
C3H10T1/2	NEHvfYdHfW6ldHnvckBie3OjeR?=		NIL6R5Y3KGi{cx?=	MV7Jcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIHTp[oZmemWwdHnheIlwdiCxZjDtc5V{\SCvZYPlcoNpgW2jbDDwcJVzcXCxdHXueEBEO0hzMGSxM\|Ih[2WubIOgeI8h[WytYXzpcoUheGixc4DoZZRie2VicH;zbZRqfmVib3Xz[Y9jdGG\|dIOgZYZ1\XJiNjDodpMtKEmFNUCgQUAxNjZ{IN88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
ASZ001	NX\EWWdETnWwY4Tpc44h[XO\|YYm=		NHz4R5c1QCCqcoO=	MlvFTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdiaX6gcY92e2ViQWPaNFAyKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDR6IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMtKEmFNUCgQUAxNjZ4IN88UU4>	NEjNVYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
M210B4	NGrNZ\|dHfW6ldHnvckBie3OjeR?=		NIrhbZQzPCCqcoO=	M3[ybmlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC56IN88UU4>	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NVYoRjJ2OUCwO\|E3RC:jPh?=
medulloblastoma cells	NEHXT\|JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MkXvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCvZXT1cIxw[myjc4TvcYEh[2WubIOgbIFz[m:{aX7nJIhmfGW{b4r5[492eyCydHPoNUBo\W6nIHL5JG1VXCCjc4PhfUwhTUN3MDC9JFEh\|ryPLh?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-
CHO	M331NWZ2dmO2aX;uJIF{e2G7			MknZRY51[WexbnnzeEBi[3Srdnn0fUBifCCvb4Xz[UBUdW9icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{BjgSCdM1jdTIguSWdiYnnu[Ilv\yCjc4PhfUwhUUN3MDC9JFEvOiEQvF2u	M4HBVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEmxOVU6Lz5zOUC5NVU2QTxxYU6=
Shh-Light2	NGj4dpRHfW6ldHnvckBie3OjeR?=		NH:3PFQ1QCCqcoO=	MXHJcohq[mm2aX;uJI9nKFOKSDDpckBud3W\|ZTDTbIguVGmpaISyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCJbHmxJJJmeG:{dHXyJIdmdmViYYPzZZkhcW5icILld4Vv[2Vib3[gV2FINCCLQ{WwJF0hOS5\|MUKg{txONg>?	NHO1SXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW0NVQ6OCd-MUm1OFE1QTB:L3G+
MEF	NH3zTXpHfW6ldHnvckBie3OjeR?=			NVXRNWZFUW6qaXLpeIlwdiCxZjDTcY8hcW5ibX;1d4UhWHSlaD3k[YZq[2mnboSgUWVHKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gV4hpNWmwZIXj[YQhT2yrMTD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHluIFnDOVAhRSBzLkWg{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-
MEF	NU\FfWVZTnWwY4Tpc44h[XO\|YYm=		M2jYRVMxKGi{cx?=	Mnn1TY5pcWKrdHnvckBw\iCVbX:gbY4hdW:3c3WgVJRkcC2mZX\pZ4lmdnRiTVXGJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiU3joMYlv\HWlZXSgS4xqNXKnc4DvcpNqfmViYnX0ZYdidGGldH;zbYRie2ViYXP0bZZqfHliYX\0[ZIhOzBiaILzJIJ6KEKndHHHUI8h[XO\|YYmsJGlEPTBiPTCxMlkh\|ryPLh?=	MkPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{S1OFEoRjJ\|MEe0OVQyRC:jPh?=
neural precursor cells	M1vB[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NUfveWI{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDu[ZVz[WxicILlZ5Vze2:{IHPlcIx{KGK7IHPvcI9vgSCob4LtZZRqd25iYYPzZZktKEWFNUCgQUAyOy52NDFOwG0v	NV\1eWZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
U87	NUTsfWMyS3m2b4TvfIlkcXS7IHHzd4F6			NWSyXZNyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTh5IHPlcIx{KGG\|c3Xzd4VlKGG\|II\pZYJqdGm2eTDpckBxemW\|ZX7j[UBw\iCkZYThJIdtfWO3cn;ubYRie2VuIFnDOVAhRSBzNT61JO69VS5?	M3H4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUG2PVA1Lz5{MEGxOlkxPDxxYU6=
U87MG	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{O2NVczKGi{cx?=	NEH2NodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCyNk42KM7:TT6=	Mki3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Mk[2OVcoRjJ{MkK2OlU4RC:jPh?=
A549	NYPyR3p5SW62aXPhcoNmeiCjc4PhfS=>			NYK3c\|VHSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iNEmg{txONg>?	M17zeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkKxPFczLz5zOEKyNVg4OjxxYU6=
DU145	MoH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NW\VXVQ4PSC3TR?=	NGjrOII6PiCqcoO=	MWTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BifCB3IIXNJIFnfGW{IEm2JIhzew>?	NEi4bmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0PVEzPSd-MUiyOFkyOjV:L3G+
DU145	M1P0dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NF3YNnAyOCC3TR?=	MUW5OkBpenN?	NEfrWpNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCjdDCxNEB2VSCjZoTldkA6PiCqcoO=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2OUGyOUc,OTh{NEmxNlU9N2F-
HEK293	NW\US4d4TnWwY4Tpc44h[XO\|YYm=			NGLsdFlKdmirYnn0bY9vKG:oIHLleIEh\2GuYXP0c5Nq\GG\|ZTDpckBJTUt{OUOgZ4VtdHN?	M{DqUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEm0O\|Y3Lz5zN{S5OFc3PjxxYU6=
22Rv	MV;GeY5kfGmxbjDhd5NigQ>?			NXPVUm1RWmWmdXP0bY9vKG:oIHX4dJJme3Orb36gc4YhWFSFSDDtVm5CKGmwIHj1cYFvKDJ{Uo[gZ4VtdHN?	NGTnfpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S5OFc3Pid-MUe0PVQ4PjZ:L3G+
PANC1	M{DxfmZ2dmO2aX;uJIF{e2G7	NXHLV\|AxOC5{IIXN	NXv2V4VMOjRiaILz	NWf4RWpRUW6qaXLpeIlwdiCxZjDIbE9IVElzLX3l[IlifGWmIGDUR2ghdVKQQTDlfJBz\XO\|aX;uJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG2IECuNkB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPS	NIfjWI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NFE4OCd-MkC0OVAyPzB:L3G+
PANC1	M2fnNWZ2dmO2aX;uJIF{e2G7	NED0WJcxNjRidV2=	MUiyOEBpenN?	NETUd2JKdmirYnn0bY9vKG:oIFjoM2dNUTFvbXXkbYF1\WRiUGTDTEBuWk6DIHX4dJJme3Orb36gbY4hcHWvYX6gVGFPSzFiY3XscJMh[XRiMD60JJVOKGGodHXyJFI1KGi{czDifUBTXC2SQ2K=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR3MEG3NEc,OjB2NUCxO\|A9N2F-
Shh Light2	M4LGe2Z2dmO2aX;uJIF{e2G7	MoDCOk4zPSC3TR?=	NG\EUGw{OCCqcoO=	NX7MSmlzUW6qaXLpeIlwdiCxZjDOMZBidG2rdH;5cIF1\WRiU3joJIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZZQhPi5{NTD1UUBi\nSncjCzNEBpenNiYomg[olz\W[ueTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzNUG3N\|EoRjF7MUWxO\|MyRC:jPh?=
U87MG	NVrEd4ZHTnWwY4Tpc44h[XO\|YYm=	NGPyb2syOCC3TR?=	NUDD[GZzPCCqcoO=	NV3Wc3NvUW6qaXLpeIlwdiCxZjDI[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCmb4fuJJJm\3WuYYTpc44hd2ZiR3zpNUBifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN?	NHW5PZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKyOlY2Pyd-MkKyNlY3PTd:L3G+
HEK293	NHXD[mpHfW6ldHnvckBie3OjeR?=	MmTCOUB2VQ>?	MW[xNEBpenN?	MYHEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NWO7Y3zvdIFucW6nIH\yc40hcHWvYX6gV41wKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XRiNTD1UUBu\WG\|dYLl[EBi\nSncjCxNEBpenNiYomgSGFRUSC\|dHHpcolv\yCkYYPl[EBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yaXOgZZN{[Xl?	Ml74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5M{[wOlMoRjJ5N{O2NFY{RC:jPh?=
HEK293	Mnj6SpVv[3Srb36gZZN{[Xl?	NGr6V2w2KHWP	NV\XZZN7OTBiaILz	NFXvVJJFcXOybHHj[Y1mdnRib3[gRm9FUVC\LXP5Z4xweGGvaX7lJIZzd21iaIXtZY4hW22xIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYSgOUB2VSCvZXHzeZJm\CCjZoTldkAyOCCqcoOgZpkhTkGFUzDhcoFtgXOrcx?=	NIjkW4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ezOlA3Oyd-Mke3N\|YxPjN:L3G+
C3H10T1/2	M4D2bWZ2dmO2aX;uJIF{e2G7	MlzLOVUvPSC2bzC0OVAxKG6P		NWLWR5hLS2:vcHX0bZRqfmViaX7obYJqfGmxbjDv[kBUdW9iaX6gcY92e2ViQ{PINVBVOS9{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhW0GJLXnu[JVk\WRiR3zpNUB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgZZQhPTVwNTD0c{A1PTByIH7NJIJ6KHGSQ2KgZY5idHm\|aYO=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-
U2OS	NVTBNJNHTnWwY4Tpc44h[XO\|YYm=	NXSzTWpkPSC3TR?=	M4XETlYhcHK\|	NGrXRWhCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHPobY1memmlIGPtc{A3OzNibYX0ZY51KGW6cILld5Nm\CCrbjDVNm9UKGOnbHzzJINw\XiycnXzd4lv\yCkZYThJIFzemW\|dHnuNk1ITlBiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCrboTyZYNmdGy3bHHyJIJmfGFiYYLy[ZN1cW5{LVfGVEBi\2e{ZXfheIUh\m:{bXH0bY9vKGG2IEWgeW0h[W[2ZYKgOkBpenNiYomgZ49v\m:lYXygcYlkem:\|Y3;wfS=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.	23599805 26137001 26859575
Immunofluorescence	Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry. PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.	24553082 28747625

体内研究

Cyclopamine 每天按50 mg/kg剂量处理小鼠，持续22天，消除HUCCT1移植瘤，且没有明显副作用。^[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天，前者诱导明显的肿瘤细胞凋亡，后者降低肿瘤质量，降低达50-60%，但是作用于BxPC3-SMOlow肿瘤没有效果。^[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤，显著抑制肿瘤转移，且和 Gemcitabine联用处理，完全废除转移。^[4]

激酶实验：^[1]	- 合并激酶实验: Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数，测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验，然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上，与Cyclopamine在37^oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上，然后在37^oC下温育。48小时后，在实验板中加入Bright-Glo或MTS，然后在492 nm处测定发光度或吸光度。通过分析反应曲线，使用R统计软件包测定IC50值。
细胞实验：^[2]	- 合并 Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116 Concentrations: 溶于DMSO, 终浓度为3 μM Incubation Time: 4天 Method: 在96孔板上，用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定，进行2和4天，然后在490 nm处通过测定光密度而测定存活细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠 Dosages: 50 mg/kg/day Administration: 皮下注射处理 (Only for Reference)

参考文献

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- 合并

溶解度 (25°C)

体外	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cyclopamine SDF

分子量	411.62
化学式	C₂₇H₄₁NO₂
CAS号	4449-51-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	11-deoxojervine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo use in mice?
回答：
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

选择性强的Smoothened抑制剂

PF-5274857 : Smoothened-selective, IC50=5.8 nM.
用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Cyclopamine

客户使用Selleck生产的Cyclopamine发表文献74篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cyclopamine SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品